Home › Funds › Two Sigma Investments › BSX

Two Sigma Investments position in BSX

BOSTON SCIENTIFIC CORP · Health Care

Two Sigma Investments reported holding 20,006,783 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$873.3M, representing 1.25% of its reported portfolio and ranking #1 among its reported holdings. Two Sigma Investments has disclosed BSX holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

Latest position (Q3 2026)20.01M sh
Reported value held$873.30M
Portfolio Weight1.25%
First reportedQ3 2021
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Two Sigma Investments's BSX position evolved

Two Sigma Investments first disclosed a stake in BSX in Q3 2021 at 4,658,517 shares (US$202.1M). The position peaked in Q3 2026 at 20,006,783 shares, worth US$873.3M. Across 21 filings, Two Sigma Investments increased the stake 9 time(s), trimmed it 11 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 20,006,783 shares valued at US$873.3M — an increase of 19,976,483 shares quarter over quarter.. Notable position changes include a 1447% increase in Q4 2022 (shares rose 8% over the following quarter), a 1299% increase in Q2 2024 (shares rose 9% over the following quarter), a 65929% increase in Q3 2026 (shares rose 2% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2021 4.66M $202.13M New
Q4 2021 4.10M $174.28M Reduce
Q1 2022 3.93M $173.86M Reduce
Q2 2022 379.00K $14.13M Reduce
Q3 2022 102.22K $3.96M Reduce
Q4 2022 1.58M $73.17M Add
Q1 2023 1.12M $56.25M Reduce
Q2 2023 2.45M $132.27M Add
Q3 2023 411.01K $21.70M Reduce
Q4 2023 99.66K $5.76M Reduce
Q1 2024 132.52K $9.08M Add
Q2 2024 1.85M $142.80M Add
Q3 2024 1.15M $96.63M Reduce
Q4 2024 741.85K $66.26M Reduce
Q1 2025 2.44M $246.22M Add
Q2 2025 2.47M $264.91M Add
Q3 2025 6.00K $585.78K Reduce
Q4 2025 3.80K $362.33K Reduce
Q1 2026 5.00K $313.75K Add
Q2 2026 30.30K $1.29M Add
Q3 2026 20.01M $873.30M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BSX and 13F data

BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 19 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), Arrowstreet Capital (US$1.24B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BSX

All BSX fund holders →

FAQ

How long has Two Sigma Investments held BSX?

Two Sigma Investments has disclosed BSX holdings in 21 of the last 21 reported quarters, going back to Q3 2021.

What is Two Sigma Investments's current position in BSX?

As of Q3 2026, Two Sigma Investments holds 20.01M shares of BSX (BOSTON SCIENTIFIC CORP), valued at $873.30M, representing 1.25% of its reported portfolio and ranking #1.

Has Two Sigma Investments been buying or selling BSX?

In the latest 13F filing (Q3 2026), Two Sigma Investments increased its position in BSX. The position peaked in Q3 2026 at 20.01M shares.

Which other funds hold BSX?

Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, Arrowstreet Capital, among 19 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.